Malignant Pleural Mesothelioma (MPM) is a highly invasive tumor that is linked to previous asbestos exposure. Combined multimodality treatment, i.e. induction chemotherapy followed by surgery, is standard of care in highly selected patients with localized disease. Platinum-doublet chemotherapy is the first choice for inoperable or advanced disease. Currently, there are no good recommendations for second-line treatment due to the lack of a clear survival benefit. We report the case of an MPM patient that showed a remarkable response through the combination of immunotherapy and radiotherapy. This case illustrates that despite failure of single-agent checkpoint inhibition, the combination of immunotherapy and radiotherapy has the potential to overcome checkpoint-inhibitor resistance in MPM.
Full Text via ClinicalKey 
Full Text Finder